ArticleJournal of the National Cancer Institute2004
Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
Article in Journal of the National Cancer Institute, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03746262 (A Pilot Study of Changes in Circulating Tumor-Specific DNA), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Changes in Circulating Tumor-Specific DNA (ctDNA) in Patients With Non-Metastatic Non-Small Cell Lung Cancer
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2005Trial
- Unraveling the Wide Spectrum of Melanoma Biomarkers.Diagnostics (Basel, Switzerland) · 2021Review
- Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease.JCO precision oncology · 2018Article
- Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.Molecular oncology · 2016Review
- Liquid Biopsies for Assessing Metastatic Melanoma Progression.Critical reviews in oncogenesis · 2016Review
- Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.The oncologist · 2016Review
- DNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm.The Analyst · 2014Article
- Epigenetic biomarkers in skin cancer.Cancer letters · 2014Review
- Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology.OncoTargets and therapy · 2013Article
- Blood biomarkers for uveal melanoma.Future oncology (London, England) · 2012Review
- Prognostic molecular biomarkers for cutaneous malignant melanoma.Journal of surgical oncology · 2011Review
- Cell-free nucleic acids as biomarkers in cancer patients.Nature reviews. Cancer · 2011Review
- Circulating nucleic acids as a new diagnostic tool.Cellular & molecular biology letters · 2010Article
- Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.The Journal of investigative dermatology · 2010Article
- Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Article
- Estrogen receptor-alpha methylation predicts melanoma progression.Cancer research · 2006Article
- Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.Current oncology reports · 2005Review
- Bov-tA short interspersed nucleotide element sequences in circulating nucleic acids from sera of cattle with bovine spongiform encephalopathy (BSE) and sera of cattle exposed to BSE.Clinical and diagnostic laboratory immunology · 2005Article
- Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2005Article
- Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma.British journal of cancer · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Although biochemotherapy appears to be a promising treatment for metastatic melanoma, its impact remains unpredictable. Microsatellite markers for loss of heterozygosity (LOH) appear to have prognostic significance when identified in primary tumors and serum and/or plasma from cancer patients. However, their association with response to systemic therapy has yet to be assessed. To determine whether microsatellite markers are associated with response to therapy, serum from 41 patients with metastatic melanoma, drawn before the initiation of biochemotherapy, was analyzed for LOH with nine microsatellite markers. During a median follow-up of 13 months, the overall response rate for these 41 patients was 56%, including 13 (32%) complete responses and 10 (24%) partial responses. LOH was detected in sera from 12 (29%) of the 41 patients. The response rate of these 12 patients was 17% (95% confidence interval [CI] = 5% to 45%), whereas that of the 29 patients without LOH was 72% (95% CI = 54% to 85%) (P =.001). All statistical tests were two-sided. The presence of LOH was statistically significant and independently associated with disease progression (multivariable analysis, P =.003). Circulating tumor DNA markers may be useful in assessing prognosis for advanced melanoma patients and their response to biochemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.